On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the coronavirus (SARS-CoV-2).

This is a novel COVID vaccine that used a second-generation adenovirus that delivered multiple proteins of the SARS-CoV-2 with the potential for long-term immunity through memory T cells.